Enhanced expression of unique gangliosides with GM2-determinant in human uterine cervical carcinoma-derived cell lines.
Monoclonal antibody YHD-06 generated by immunization with GM2 reacted with gangliosides with GM2-determinant, i.e., GM2, GalNAc-GM1b and GalNAc-GD1a, among which GalNAc-GD1a was characterized as an antigen of autoimmune peripheral neuropathies including Guillain-Barré syndrome. When glycolipids were examined by TLC-immunostaining with YHD-06 in seven human cervical carcinoma-derived cell lines, GM2 was found in all cell lines, amounting to 15.5 % to 57.5 % of total gangliosides. Whereas GalNAc-GD1a was present in three cell lines, amounting to 5.4-17.5 % of total gangliosides, and GalNAc-GM1b in four cell lines in amounts of less than 2 %. The elevated amounts of gangliosides with GM2 determinant were closely correlated with the relative intensities of gene expression of GalNAc transferase, this being characteristic of cervical carcinoma-derived cells. However, in tissues from patients with several histological types of cervical carcinomas, GM3 was ubiquitously expressed in amounts of more than 66 % of total gangliosides, GM2 was expressed in only five of 15 tissues, and both GalNAc-GM1b and GalNAc-GD1a were not even detected in trace amounts. Since GM1 was detected in all tissues in amounts of less than 0.06 μg/mg dried tissue, all cervical carcinoma tissues were revealed to exhibit GM2 synthesis, indicating that enhanced synthesis of gangliosides with GM2 determinant is a characteristic of cultivated cells in vitro. Similarly, although I(3)SO3-GalCer was not present in the squamous cell carcinoma (SCC) tissues, SCC-derived cells selectively expressed II(3)SO3-LacCer. Since enhanced synthesis of GM2 has been reported in SV-40 virus-transfected fibroblasts, papilloma virus might be involved in the expression of GM2 in cervical carcinoma-derived cells.
Department of Obstetrics and Gynecology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Kyoko
K
Tanaka
Department of Obstetrics and Gynecology, School of Medicine, Tokai University, 143 Shimo-Kasuya, Isehara, Kanagawa, 259-1193, Japan.
Masaki
M
Miyazawa
Department of Obstetrics and Gynecology, School of Medicine, Tokai University, 143 Shimo-Kasuya, Isehara, Kanagawa, 259-1193, Japan.
Mikio
M
Mikami
Department of Obstetrics and Gynecology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Daisuke
D
Aoki
Department of Obstetrics and Gynecology, St Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa, 216-8511, Japan.
Kazushige
K
Kiguchi
Faculty of Science and Technology, Kinki University, 3-4-1 Kowakae, Higashiosaka, Osaka, 577-8502, Japan. iwamori@life.kindai.ac.jp.
Masao
M
Iwamori
D005260:Female; D005678:G(M2) Ganglioside / Q000096:biosynthesis*; D015972:Gene Expression Regulation, Neoplastic; D006367:HeLa Cells; D006801:Humans; D002583:Uterine Cervical Neoplasms / Q000378:metabolism*
D005678:G(M2) Ganglioside
Glycolipid; Glycosyltransferase; Gynecological cancer; Monoclonal antibody; a-series ganglioside